Feb 4 2010
Advanced
Cancer Therapeutics (ACT), a for-profit private company dedicated to
bringing new anti-cancer therapies to market, today announced that it
has signed an agreement to leverage the computational chemistry
expertise of Dr. John Trent, Associate Professor, Department of Medicine
at the University of Louisville’s James
Graham Brown Cancer Center (Brown Cancer Center), to accelerate the
identification of new clinical candidates for the prevention and
treatment of cancer.
“ACT is pleased to be working with Dr. Trent as we collaborate to
accelerate the discovery process to develop potentially lifesaving
therapeutics for cancer patients”
As part of this agreement, over the next twelve months Dr. Trent will
provide contract work for ACT and interface with ACT’s medicinal
chemists to identify the best preclinical candidates for ACT’s top two
small molecule compound programs addressing two novel cancer targets in
the area of cancer metabolism. These programs include
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) and
Choline Kinase (CK). ACT obtained worldwide exclusive licenses from the
Brown Cancer Center to the PFKFB program in 2008 and for the CK program
in 2009.
To date, ACT has rationally designed and synthesized over 200 novel
small molecule compounds against both PFKFB and CK targets. The company
has been able to identify several potential preclinical candidates with
desired selectivity and potency parameters and other attractive
attributes, bringing them closer to initiating toxicology studies that
would support an investigational new drug (IND) application.
Establishing this collaboration with Dr. Trent will allow the company to
integrate computational chemistry into ACT’s medicinal chemistry
activities and should enable ACT to select the best preclinical
candidate for both the PFKFB and CK program, as well as prioritize
related backup compounds.
“ACT is pleased to be working with Dr. Trent as we collaborate to
accelerate the discovery process to develop potentially lifesaving
therapeutics for cancer patients,” said Randall Riggs, President & CEO
of ACT. “His computational chemistry efforts will complement our current
medicinal chemistry efforts which look at the crystal structure of each
target to help ACT rationally design and rapidly identify the best
anti-cancer products.”
Source:
Advanced Cancer Therapeutics